Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Apr;61(4):597–604. doi: 10.1038/bjc.1990.133

An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research.

N S Rawson 1, J Peto 1
PMCID: PMC1971381  PMID: 2158808

Abstract

Several studies of small cell lung cancer (SCLC) treatments have been performed in the United Kingdom. In some, prognostic factor analyses were carried out but the results were not entirely consistent. The Lung Cancer Subcommittee of the United Kingdom Coordinating Committee on Cancer Research (UKCCCR) consequently initiated an overview of these studies with the aim of identifying the important prognostic factors using a large number of patients. Information on almost 4,000 patients was available, but it was necessary to perform analyses on smaller subsets because the variables recorded in individual studies were inconsistent. A number of variables contributed significantly to the prediction of likely survival over the 6 months after starting treatment, but performance status (PS), alkaline phosphatase (AlkP) and disease stage were shown to be the most important; aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) may also be useful. A prognostic index was devised for this initial period and validated using independent data. For patients who survived the first 6 months, the pre-treatment variables important for prognosis in the 6-24 month period were stage, PS and plasma sodium (Na). The Subcommittee recommends that performance status, disease stage, AlkP, Na, AST and LDH should be measured in all future SCLC studies to assist comparisons between studies and possibly the selection of patients for different treatment strategies. The additional recording of five other variables would allow a more definitive overview to be performed at some future date.

Full text

PDF
597

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allan S. G., Gregor A., Cornbleet M. A., Leonard R. C., Smyth J. F., Grant I. W., Crompton G. K. Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer. Cancer Chemother Pharmacol. 1984;13(2):106–108. doi: 10.1007/BF00257124. [DOI] [PubMed] [Google Scholar]
  2. Cerny T., Blair V., Anderson H., Bramwell V., Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer. 1987 Feb 15;39(2):146–149. doi: 10.1002/ijc.2910390204. [DOI] [PubMed] [Google Scholar]
  3. Cullen M., Morgan D., Gregory W., Robinson M., Cox D., McGivern D., Ward M., Richards M., Stableforth D., Macfarlane A. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trial. Cancer Chemother Pharmacol. 1986;17(2):157–160. doi: 10.1007/BF00306746. [DOI] [PubMed] [Google Scholar]
  4. Morittu L., Earl H. M., Souhami R. L., Ash C. M., Tobias J. S., Geddes D. M., Harper P. G., Spiro S. G. Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. Br J Cancer. 1989 May;59(5):801–804. doi: 10.1038/bjc.1989.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Smyth J. F., Fowlie S. M., Gregor A., Crompton G. K., Busuttil A., Leonard R. C., Grant I. W. The impact of chemotherapy on small cell carcinoma of the bronchus. Q J Med. 1986 Oct;61(234):969–976. [PubMed] [Google Scholar]
  6. Souhami R. L., Bradbury I., Geddes D. M., Spiro S. G., Harper P. G., Tobias J. S. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res. 1985 Jun;45(6):2878–2882. [PubMed] [Google Scholar]
  7. Souhami R. L., Geddes D. M., Spiro S. G., Harper P. G., Tobias J. S., Mantell B. S., Fearon F., Bradbury I. Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial. Br Med J (Clin Res Ed) 1984 Jun 2;288(6431):1643–1646. doi: 10.1136/bmj.288.6431.1643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Spiro S. G., Souhami R. L., Geddes D. M., Ash C. M., Quinn H., Harper P. G., Tobias J. S., Partridge M., Eraut D. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer. 1989 Apr;59(4):578–583. doi: 10.1038/bjc.1989.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Thatcher N., Barber P. V., Hunter R. D., Carroll K. B., Jegarajah S., Wilkinson P. M., Crowther D. 11-week course of sequential methotrexate, thoracic irradiation, and moderate-dose cyclophosphamide for "limited"-stage small-cell bronchogenic carcinoma. A study from the Manchester Lung Tumour Group. Lancet. 1982 May 8;1(8280):1040–1043. doi: 10.1016/s0140-6736(82)92099-2. [DOI] [PubMed] [Google Scholar]
  10. Thatcher N., Cerny T., Stout R., Anderson H., Barber P. V., Wolstenholme R. J., Barnes P., Deiraniya A. Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer. Cancer. 1987 Nov 15;60(10):2382–2387. doi: 10.1002/1097-0142(19871115)60:10<2382::aid-cncr2820601006>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  11. Thatcher N., James R. D., Steward W. P., Barber P. V., Feinmann D., Lawson B. A., Carroll K. B. Three months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer. Cancer. 1985 Sep 15;56(6):1332–1336. doi: 10.1002/1097-0142(19850915)56:6<1332::aid-cncr2820560619>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  12. Thatcher N., Stout R., Smith D. B., Grötte G., Winson M., Bassett H., Carroll K. B. Three months treatment with chemotherapy and radiotherapy for small cell lung cancer. Br J Cancer. 1985 Sep;52(3):327–332. doi: 10.1038/bjc.1985.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Vincent M. D., Ashley S. E., Smith I. E. Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging. Eur J Cancer Clin Oncol. 1987 Nov;23(11):1589–1599. doi: 10.1016/0277-5379(87)90436-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES